- Home
- PRAA vs BCAX Comparison
PRAA vs BCAX Comparison
Compare PRAA & BCAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRAA
- BCAX
- Stock Information
- Founded
- PRAA 1996
- BCAX 2018
- Country
- PRAA United States
- BCAX United States
- Employees
- PRAA N/A
- BCAX N/A
- Industry
- PRAA Finance: Consumer Services
- BCAX
- Sector
- PRAA Finance
- BCAX
- Exchange
- PRAA Nasdaq
- BCAX NYSE
- Market Cap
- PRAA 790.6M
- BCAX 670.9M
- IPO Year
- PRAA N/A
- BCAX 2024
- Fundamental
- Price
- PRAA $18.25
- BCAX $14.88
- Analyst Decision
- PRAA Strong Buy
- BCAX Buy
- Analyst Count
- PRAA 2
- BCAX 7
- Target Price
- PRAA $32.00
- BCAX $29.67
- AVG Volume (30 Days)
- PRAA 328.8K
- BCAX 522.8K
- Earning Date
- PRAA 05-05-2025
- BCAX 05-16-2025
- Dividend Yield
- PRAA N/A
- BCAX N/A
- EPS Growth
- PRAA N/A
- BCAX N/A
- EPS
- PRAA 1.79
- BCAX N/A
- Revenue
- PRAA $1,114,524,000.00
- BCAX N/A
- Revenue This Year
- PRAA $7.67
- BCAX N/A
- Revenue Next Year
- PRAA $5.67
- BCAX N/A
- P/E Ratio
- PRAA $10.26
- BCAX N/A
- Revenue Growth
- PRAA 38.87
- BCAX N/A
- 52 Week Low
- PRAA $15.94
- BCAX $8.91
- 52 Week High
- PRAA $28.64
- BCAX $28.09
- Technical
- Relative Strength Index (RSI)
- PRAA 48.46
- BCAX N/A
- Support Level
- PRAA $16.02
- BCAX N/A
- Resistance Level
- PRAA $18.40
- BCAX N/A
- Average True Range (ATR)
- PRAA 1.16
- BCAX 0.00
- MACD
- PRAA 0.15
- BCAX 0.00
- Stochastic Oscillator
- PRAA 64.53
- BCAX 0.00
About PRAA PRA Group Inc.
PRA Group Inc is a leader in acquiring and collecting nonperforming loans. The company returns capital to banks and other creditors to help expand financial services for consumers in the Americas, Europe, and Australia. It is also engaged in providing fee-based services on class action claims recoveries in the United States. The company's portfolio segments include; Core, which is engaged in purchasing and collecting nonperforming loans, which the originators have not chosen not to pursue, and the Insolvency segment which is engaged in purchasing and collecting nonperforming loans where the customer is involved in a bankruptcy proceeding.
About BCAX BICARA THERAPEUTICS INC
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.